Triple-action clotrimazole gel for recurrent vaginal yeast infections

Overview

This innovative solution addresses the challenge of recurrent vaginal yeast infections using a solidified reversed micellar solution (SRMS) gel formulation. The gel integrates clotrimazole, a widely-used antifungal agent, with a muco-adhesive and thermosensitive biopolymer, alongside a biofilm disruptor and lactic acid producer. This combination aims to enhance clotrimazole's solubility and bioavailability, increase antifungal efficacy, and prolong retention at the vaginal site. The formulation also supports the restoration of healthy vaginal flora, potentially reducing the recurrence of infections.

Technical specifications

The gel leverages SRMS technology to develop a multifunctional delivery system. Key components include:

• Clotrimazole (CMZ): Provides antifungal action
• Muco-adhesive biopolymer: Ensures prolonged retention
• Biofilm disruptor: Enhances antifungal efficacy
• Lactic acid producer: Helps restore healthy vaginal flora
• Chitosan: Acts as an antifungal adjuvant
• The formulation is designed to be simple to manufacture and scalable, utilizing GRAS-status excipients.

Technology readiness level

This technology is currently at TRL 2, indicating the concept and application have been formulated. Future validation plans include developing SRMS-based liposomal formulations and assessing physicochemical performance, localized drug delivery, fungal clearance, biofilm disruption, safety, and flora restoration. The study is projected to take three years, and partnerships are sought for resources and support in this development phase.